CClinicalTrials.gg
Sign In
Not yet recruitingNCT07809178ChTTSRUIAUpdated Sep 9, 2026

China Treatment Trial for Tumor in Sellar Region With Unruptured Intracranial Aneurysm

An observational study in Unruptured Intracranial Aneurysms, Pituitary Neuroendocrine Tumor and Craniopharyngioma, sponsored by Cheng sen. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-09.

Sponsored by Cheng sen · Observational

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
608
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The goal of this observational study is to learn about the treatment strategies for tumor in sellar region with unruptured intracranial aneurysms in the Chinese population. The main question it aims to answer is: For patients with tumor in sellar region combined with unruptured intracranial aneurysms, which condition should be treated first?

Read the detailed description

The goal of this observational study is to clarify the treatment strategies for tumor in sellar region with unruptured intracranial aneurysms in the Chinese population aged from 18 to 75. The main question it aims to answer is:

  • What is the appropriate treatment strategy for patients diagnosed with tumor in sellar region with unruptured intracranial aneurysms?
  • Should the tumor be resected first followed by aneurysm treatment, or should the aneurysm be treated prior to tumor resection? Alternatively, is tumor resection alone with regular observation of the aneurysm a viable option?
  • What are the patient's intraoperative risks, postoperative complications, and prognosis?

Participants are required to:

  • Provide detailed medical records.
  • Complete laboratory tests and imaging examinations at scheduled time points and cooperate with neurosurgeons for follow-up visits after the relevant treatments.

This is an observational study. It solely collects patients' pre-operative, intra-operative, and post-operative follow-up information and does not influence the patient's treatment process or clinical decision-making.

02

Conditions studied

  • Unruptured Intracranial Aneurysms
  • Pituitary Neuroendocrine Tumor
  • Craniopharyngioma
  • Meningioma
  • Germinoma
  • Rathke Cleft Cysts
  • Chordoma
  • Optic Pathway Glioma
  • Hypothalamic Neoplasms

Keywords

  • Tumor in sellar region
  • Unruptured intracranial aneurysms
03

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients diagnosed of tumor in sellar region with unruptured intracranial aneurysms in the Chinese population

Inclusion criteria

  1. Preoperative enhanced head MRI showing a suspected diagnosis of a sella region lesion, and preoperative head CTA/DSA confirming an unruptured intracranial aneurysm.
  2. Patients with primary sella region tumor and unruptured intracranial aneurysms that have not previously accepted surgical treatment.
  3. Patients with tumor in sellar region requiring craniotomy or endoscopic transnasal surgery and/or an aneurysm requiring craniotomy, endovascular treatment, or observation only.
  4. The patients are in good general health, without severe underlying medical conditions, and capable of tolerating surgical treatment.
  5. Patients or their legal guardians have signed an informed consent form and voluntarily agreed to participate in the clinical trial.

Exclusion criteria

Exclusion Criteria:

  1. Patients with recurrent sella region tumors.
  2. Patients with previously treated intracranial aneurysm.
  3. Pregnant or breastfeeding women.
  4. Any other condition that, in the investigator's judgment, makes the patient unsuitable for trial participation.
04

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
608 participants (estimated)
Target follow-up
2 Years
Patient registry
Yes

Groups and cohorts

  • Priority to Tumor

    Tumor resection followed by aneurysm treatment

    Procedure: Tumor resection followed by aneurysm treatment

  • Priority to Aneurysm

    Aneurysm treatment followed by tumor resection

    Procedure: Aneurysm treatment followed by tumor resection

  • Only Tumor

    Tumor resection without aneurysm treatment but observation

    Other: Observation

Interventions

  • ProcedureTumor resection followed by aneurysm treatment

    Tumor resection followed by aneurysm treatment

  • ProcedureAneurysm treatment followed by tumor resection

    Aneurysm treatment followed by tumor resection

  • OtherObservation

    Tumor resection without aneurysm treatment but observation

05

What researchers measure

Primary outcomes

  1. Aneurysm progression

    The diameter of aneurysm neck, the diameter of aneurysm dome, the volume of aneurysm, aneurysm rupture status

    Time frame: From enrollment to the end of treatment at 24 months

  2. Tumor related complication and progression

    The related complication and progression of tumor in sellar region: pituitary hormone level, visual acuity and visual field, hydrocephalus and tumor recurrence.

    Time frame: From enrollment to the end of treatment at 24 months

06

Study locations

1 site
  • Beijing Tiantan Hospital affiliated to Capital Medical University
    Beijing, China 100070, China
07

References and documents

Publications

  • Almeida Silva JM, Campos RR, Souza RR, Sette Dos Santos ME, Aguiar GB. Spontaneous subarachnoid haemorrhage from rupture of an anterior communicating artery aneurysm in a patient with pituitary macroadenoma. Neurocirugia (Astur). 2014 Mar-Apr;25(2):81-5. doi: 10.1016/j.neucir.2013.03.005. Epub 2013 Jul 9. PubMed 23845268 ↗
  • Schwab KE, Gailloud P, Wyse G, Tamargo RJ. Limitations of magnetic resonance imaging and magnetic resonance angiography in the diagnosis of intracranial aneurysms. Neurosurgery. 2008 Jul;63(1):29-34; discussion 34-5. doi: 10.1227/01.NEU.0000335068.53190.46. PubMed 18728566 ↗
  • Oshino S, Nishino A, Suzuki T, Arita H, Tateishi A, Matsumoto K, Shimokawa T, Kinoshita M, Yoshimine T, Saitoh Y. Prevalence of cerebral aneurysm in patients with acromegaly. Pituitary. 2013 Jun;16(2):195-201. doi: 10.1007/s11102-012-0404-x. PubMed 22752346 ↗
  • de Sena Barbosa MG, Otavio da Silva V, Santos Ferreira LH, de Souza RLV, Pipek LZ, de Oliveira Almeida G, Figueiredo EG, Rabelo NN, Chaurasia B. Intracranial aneurysm coexisting with pituitary adenoma: a systematic review. Ann Med Surg (Lond). 2024 Oct 25;86(12):7232-7237. doi: 10.1097/MS9.0000000000002692. eCollection 2024 Dec. PubMed 39649870 ↗
  • Cai K, Jia Y, Jin L, Qiao N, Xiao Y, Wu W, Ru S, Liu F, Liu C, Cao L, Gui S. Adult craniopharyngioma concomitant with unruptured intracranial aneurysms: incidence, risk factors, and treatment strategies. J Neurosurg. 2024 Jun 14;141(6):1712-1722. doi: 10.3171/2024.3.JNS232258. Print 2024 Dec 1. PubMed 38875730 ↗

Individual participant data

Plan to share: Undecided — The IPD used and/or analyzed during the current study are available from the researcher on reasonable request.

08

Registry details

Key details

Study ID
NCT07809178
Lead sponsor
Cheng sen
Collaborators
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, West China Hospital, Xijing Hospital, Shandong Provincial Hospital, The First Affiliated Hospital of Anhui Medical University, First Affiliated Hospital of Chongqing Medical University, Shengjing Hospital, Lanzhou University Second Hospital, The First Hospital of Jilin University, People's Hospital of Xinjiang Uygur Autonomous Region, Guangdong Provincial Hospital of Traditional Chinese Medicine, Huashan Hospital, Jinling Hospital, China
Responsible party
Cheng sen (Principal Investigator, Capital Medical University) — Sponsor-investigator
First posted
Sep 9, 2026
Start date
Sep 1, 2026 (estimated)
Primary completion
Sep 1, 2028 (estimated)
Completion
Sep 1, 2031 (estimated)
Last update
Sep 9, 2026

Study contacts

Sen Cheng, MD
Contact
dr.sencheng@hotmail.com
+8615313520109

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Craniopharyngioma→

Start the discussion